Member Info for BuenaVista

How old are you Watching, because you come across as about 12.

Well, we already know Aldebaran as Monkeysponge, an uber-ramper trader who'll spam the BB with 'expert' opinion 🤣🤣🤣 until his get-out day arrives - my money this time is on 'Pipeline Day' given that last time it was 'AVA6000 Data Day' - and then disappear only to reappear, having bought at his low, when the SP looks like peaking again. Act on his BS at your own peril... DYOR and use him for your own advantage, why not?

GLALTH

Https://www.ft.com/content/cc3e83b4-79eb-46fa-944f-7b2fc909051a

I can read it. It has several graphics that won't reproduce here. I assume you've reached your free view limit. Do you have another device you could access it from?

OK, understood now.

These are two ESMO Congress 2024 pages pertinent to abstracts. Not sure what they mean as regards deadlines but can't see Avacta stopping a trial just to present data at a conference, particularly there is a lead in time to get abstracts published.

https://www.esmo.org/meeting-calendar/esmo-congress-2024/abstracts

https://www.esmo.org/meeting-calendar/esmo-congress-2024/press-media

@LL, do you think they'd RNS that or wait to piggy back it as they've done for C1 and C2 with something else like the ESMP poster?

I asked the same question when gmcc said Chris Twelves was presenting. Details of the POSTER (again a poster 🙄 rather than a presentation to a large seated audience) was in an image in a Twitter post. So it's not an Avacta presentation, but Avacta should, if they have any sense - and the budget to cover it! - announce it as in least a REACH, if not an RNS, some time before the poster presentation on Saturday 14 September. Maybe ,at the same time, we'll get news of C4 having already started.🤞

Clinicians may or may not be bound by confidentiality clauses - obviously Avacta need to be in total control of what is said publicly about AVA6000, including discussion with professional colleagues as that puts the knowledge into the public domain.

The reason AVA6000 is not well known amongst the oncology community is because Avacta have put bogger all into the public domain beyond a couple of conference abstracts with scant detail.

The CRUK mention shows just how hard it is for people to get their heads around what AVA6000 and the pre|CISION platform are, even for a 'specialist' organisation such as CRUK.🙄😕

His Austin A30 no less, with sunroof for added room.

Twocancarmoon is just miffed because all that jumping up and down has aggravated the rusty hole in his vintage car.

Well she has a family and it's summer holiday time and the Phillies are probably playing the New Orleans Nonces or some such.

Monkeysponge/Aldebaran/GBanks is a trader and prolific (expert) poster when ramping. Get taken in by it all at your own peril. One day he will sell and disappear, only to reappear with a different username after buying low when he senses he can ramp a moving price further up, only to rinse and repeat.

Thank you gmcc

Can someone please help LDA with reading?

Is this a thing? Where was it announced about this presentation happening?

A perfect summation Timster.

@B2HS2L, SOFIE retain exclusive rights to [18F]FAPI-74 within the US, which is where they are based and where, I'm 99.99% sure, they do the PET scanning. (I remember Alan saying that the scanning has to be done close to the production of the radioisotopes due to rapid half-life decay. But that was Alan.)

"Chalfont St Giles, UK – 11 October, 2023: GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE), a Virginia, U.S.-based company, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP). Financial terms were not disclosed. Based on this agreement, GE HealthCare will take on global rights for [68Ga]FAPI-46 and outside-US rights for [18F]FAPI-74, originally developed at Heidelberg University in Germany, and both currently in Phase II clinical trials in the U.S. ([68Ga]FAPI-46 (NCT05262855)[2] and [18F]FAPI-74 (NCT05641896)[3]). SOFIE will continue its clinical development and commercialization program with [18F]FAPI-74 in the U.S."

"... but SOFIE are also seeing results as they happen."

The RNS does not say that. The RNS says:

"The sub-study through partnership with SOFIE utilising **baseline** [18F]FAPI-74 PET scanning in the AVA6000 Phase 1 trial has commenced and is **designed to better characterise** in a subset of patients the whole-body tumor expression of the target of the pre|CISION™ molecule and **levels of fibroblast activation protein ("FAP") expression**, ..."

SOFIE are involved in characterising selected patients' (which I suspect are just those in the US who are close to the PET diagnostic facility) cancers before treatment with AVA6000 in order to learn more about the levels of FAP in various cancers - something that, going forward, will be very useful in deciding which cancers are most suitable for treatment and hence for Phase 2 trials.